Hypoglycemic and anti-depressant effects of Zuogui Jiangtang Jieyu formulation in a model of unpredictable chronic mild stress in rats with diabetes mellitus

Experimental and Therapeutic Medicine

Volumn 8, Issue 1, 2014, Pages 281-285

  Wang, Yu Hong ^a,b   Yin, Ling Tao ^b   Yang, Hui ^a   Li, Xin Liang ^b   Wu, Kai Ge ^c  

^a Hunan Key Laboratory of Chinese Materia Medica Powder Innovative Drugs Established by Provincial and Ministry   (China)

^b HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Diabetes mellitus with depression; Zuogui Jiangtang Jieyu formulation

Indexed keywords

CHINESE DRUG; CHOLESTEROL; FLUOXETINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZUOGUI JIANGTANG JIEYU;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MORRIS WATER MAZE TEST; NONHUMAN; OPEN FIELD TEST; RAT;

EID: 84901292575     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1681     Document Type: Article

References (26)

1. Lavergne F and Jay TM: A new strategy for antidepressant prescription. Front Neurosci 4: 192, 2010.
2. Fujitsuka N, Asakawa A, Hayashi M, et al: Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biol Psychiatry 65: 748-759, 2009.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT and Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757, 2006.
4. Ning G and Bloomgarden Z: Diabetes in China: prevalence, diagnosis, and control. J Diabetes 5: 372, 2013.
5. Shaw JE, Sicree RA and Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14, 2010.
6. Lin CH, Lee YY, Liu CC, Chen HF, Ko MC and Li CY: Urbanization and prevalence of depression in diabetes. Public Health 126: 104-111, 2012.
7. Ali S, Stone MA, Peters JL, Davies MJ and Khunti K: The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med 23: 1165-1173, 2006.
8. Barnard KD, Skinner TC and Peveler R: The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med 23: 445-448, 2006.
9. Katon W, Russo J, Lin EH, et al: Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensification? Psychosom Med 71: 965-972, 2009.
10. Egede LE and Ellis C: Diabetes and depression: global perspectives. Diabetes Res Clin Pract 87: 302-312, 2010.
11. Schram MT, Baan CA and Pouwer F: Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Curr Diabetes Rev 5: 112-119, 2009.
12. Erenmemisoglu A, Ozdogan UK, Saraymen R and Tutus A: Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 51: 741-743, 1999.
13. Goodnick PJ: Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 13: 31-41, 2001.
14. Lee HJ, Lee SY, Kim JH, et al: Depressive mood and quality of life in functional gastrointestinal disorders: differences between functional dyspepsia, irritable bowel syndrome and overlap syndrome. Gen Hosp Psychiatry 32: 499-502, 2010.
15. Kim HS, Rhee PL, Park J, et al: Gender-related differences in visceral perception in health and irritable bowel syndrome. J Gastroenterol Hepatol 21: 468-473, 2006.
16. Tang HS: Study on relative problems of acupuncture and moxibustion for treatment of simple obesity. Zhongguo Zhen Jiu 28: 522-524, 2008 (In Chinese).
17. Salpeter SR, Buckley NS, Kahn JA and Salpeter EE: Meta-analysis: Metformin treatment in persons at risk for diabetes mellitus. Am J Med 121: 149-157, 2008.
18. Selvin E, Bolen S, Yeh HC, et al: Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168: 2070-2080, 2008.
19. Srinivasan K, Viswanad B, Asrat L, Kaul CL and Ramarao P: Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52: 313-320, 2005.
20. Willner P: Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 134: 319-329, 1997.
21. Wong TP, Howland JG, Robillard JM, et al: Hippocampal long-term depression mediates acute stress-induced spatial memory retrieval impairment. Proc Natl Acad Sci USA 104: 11471-11476, 2007.
22. Cassano P and Fava M: Depression and public health: an overview. J Psychosom Res 53: 849-857, 2002.
23. Cassileth BR, Lusk EJ, Strouse TB, et al: Psychosocial status in chronic illness. A comparative analysis of six diagnostic groups. N Engl J Med 311: 506-511, 1984.
24. Noël PH, Williams JW Jr, Unützer J, et al: Depression and comorbid illness in elderly primary care patients: impact on multiple domains of health status and well-being. Ann Fam Med 2: 555-562, 2004.
25. Xu Y, Barish PA, Pan J, Ogle WO and O'Donnell JM: Animal models of depression and neuroplasticity: assessing drug action in relation to behavior and neurogenesis. Methods Mol Biol 829: 103-124, 2012.
26. Yan HC, Cao X, Das M, Zhu XH and Gao TM: Behavioral animal models of depression. Neurosci Bull 26: 327-337, 2010.